SCHEMBL7909257

SCHEMBL7909257

O=C(c1ccc(-c2ccc(F)cc2)cc1)N1CCC(C(=O)NC2(c3ccc(F)cc3)CC2)(c2ccc(F)cc2)CC1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.46
SLC6A7 Q99884 2/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
HSD11B1 P28845 3/20 0.44
GPR183 P32249 1/20 0.41
HDAC1 Q13547 2/20 0.41
HDAC3 O15379 1/20 0.41
CYP2C19 P33261 1/20 0.41
HTT P42858 1/20 0.41
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA7 P43166 1/20 0.40
CA9 Q16790 1/20 0.40
CA14 Q9ULX7 1/20 0.40
FASN P49327 2/20 0.40
EPHX2 P34913 2/20 0.40
HTR2B P41595 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13092381 0.86 TACR3 (0.44) MEN1KMT2A
SCHEMBL13092365 0.84 TACR3 (0.42) MEN1KMT2AHDAC1CYP2C19FASN
SCHEMBL7907121 0.83 ALDH1A1 (0.53) MEN1KMT2AHTT
SCHEMBL3102338 0.82 OPRL1 (0.53) PTPN1SLC6A7MEN1KMT2ACYP2C19
SCHEMBL3107003 0.82 PTPN1 (0.50) PTPN1SLC6A7MEN1KMT2AHSD11B1
SCHEMBL378380 0.82 SLC6A7 (0.54) PTPN1SLC6A7MEN1KMT2AHSD11B1
SCHEMBL3088857 0.80 LMNA (0.43) PTPN1SLC6A7MEN1KMT2AHSD11B1
SCHEMBL13092254 0.80 KIT (0.44) PTPN1SLC6A7MEN1KMT2AHSD11B1
SCHEMBL7907727 0.80 SLC6A7 (0.50) PTPN1SLC6A7MEN1KMT2AHSD11B1
SCHEMBL7900551 0.79 HSD11B1 (0.35) HSD11B1CYP2C19HTTEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed
WO-2010106081-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HTR3A, OPRL1, OPRK1 PTPN1 1883/4885SLC6A7 105/4885MEN1 4869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.